All data are based on the daily closing price as of July 4, 2025
t
TaiMed Biologics
4147.TWO
3.11 USD
-0.08
-2.51%
Overview
Last close
3.11 usd
Market cap
848.22M usd
52 week high
3.60 usd
52 week low
2.03 usd
Target price
4.9 usd
Valuation
P/E
N/A
Forward P/E
1111.1111
Price/Sales
40.4203
Price/Book Value
6.1286
Enterprise Value
809.35M usd
EV/Revenue
38.5053
EV/EBITDA
543.5886
Key financials
Revenue TTM
21.02M usd
Gross Profit TTM
8.11M usd
EBITDA TTM
-3.49M usd
Earnings per Share
-0.03 usd
Dividend
N/A usd
Total assets
148.40M usd
Net debt
N/A usd
About
TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. It develops and markets Trogarzo IV infusion and Trogarzo IV push, a monoclonal antibody for HIV treatment. The company is also developing TMB-365, a monoclonal antibody used for HIV treatment and prevention which has completed a phase-1 clinical trial; and TMB-365 and TMB-380 combination, a monoclonal antibody combination therapy for HIV that is in phase-1b/2a clinical trial, as well as antibody-drug conjugates, for cancer treatment. In addition, it offers contract development and manufacturing services. The company has a research and development agreement for Trogarzo TMB-355 with Genentech and Biogen Inc., and authorizes Samsung Biologics to produce TMB-355. TaiMed Biologics Inc. was incorporated in 2007 and is headquartered in Taipei City, Taiwan.